Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 779 participants.

Also called NCT02991118

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 779 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02991118
  • EudraCT 2016-003486-26
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02991118. Randomized; triple masking; primary purpose treatment. Start 2016-11-18 (actual); primary completion 2018-08-22 (actual). Results posted on 2020-04-27.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk
Acronym
CLEAR Wisdom
Condition
Hypercholesterolemia
Condition
Atherosclerotic Cardiovascular Disease
Intervention (Drug)
bempedoic acid
Intervention (Drug)
placebo
Lead sponsor
Esperion Therapeutics, Inc. (class: industry)

Record details

Record id
cardio:ct-nct02991118
Content hash
e9cbbfa71872a43fc91b8931f121f86f800cd2aab74234fb06bca98ef6d3049c